Abstract
Background and aims: Long non-coding RNA (lncRNA) FOXD2 adjacent opposite strand RNA 1 (FOXD2-AS1) is aberrantly expressed in various cancers and associated with cancer progression. A comprehensive meta-analysis was performed based on published literature and data in the Gene Expression Omnibus database, and then the Cancer Genome Atlas (TCGA) dataset was used to assess the clinicopathological and prognostic value of FOXD2-AS1 in cancer patients.Methods: Gene Expression Omnibus databases of microarray data and published articles were used for meta-analysis, and TCGA dataset was also explored using the GEPIA analysis program. Hazard ratios (HRs) and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the role of FOXD2-AS1 in cancers.Results: This meta-analysis included 21 studies with 2391 patients and 25 GEO datasets with 3311 patients. The pooled HRs suggested that highly expressed FOXD2-AS1 expression was correlated with poor overall survival (OS) and disease-free survival (DFS). Similar results were obtained by analysis of TCGA data for 9502 patients. The pooled results also indicated that FOXD2-AS1 expression was associated with bigger tumor size and advanced TNM stage, but was not related to age, gender, differentiation and lymph node metastasis.Conclusion: The present study demonstrated that FOXD2-AS1 is closely related to tumor size and TNM stage. Additionally, increased FOXD2-AS1 was a risk factor of OS and DFS in cancer patients, suggesting FOXD2-AS1 may be a potential biomarker in human cancers.
Highlights
Malignant tumors pose a great threat to human health [1]
LncRNA was initially considered as noise, but the development of high-throughput sequencing and gene chip technology has revealed that many Long non-coding RNA (lncRNA) are abnormally expressed in tumor tissues
We set the inclusion criteria for articles in this meta-analysis as follows: (1) use of qRT-PCR or RNA-seq data to measure the expression of FOXD2-AS1 in tumor tissues; (2) reported association between FOXD2-AS1 expression and clinicopathological characteristics and prognosis; and (3) reported specific hazard ratios (HRs) with 95% confidence interval (CI) or inclusion of sufficient data so that these parameters can be calculated by survival curves
Summary
Malignant tumors pose a great threat to human health [1]. Each year, there are approximately 14 million new cases of malignant tumors worldwide and more than 8.2 million deaths [2,3]. LncRNA was initially considered as noise, but the development of high-throughput sequencing and gene chip technology has revealed that many lncRNAs are abnormally expressed in tumor tissues. These lncRNAs are closely related to tumor resistance, cancer development, invasion and metastasis, suggesting that lncRNAs may be a new class of predictors or therapeutic targets for cancers [7,8]. A comprehensive meta-analysis was performed based on published literature and data in the Gene Expression Omnibus database, and the Cancer Genome Atlas (TCGA) dataset was used to assess the clinicopathological and prognostic value of FOXD2-AS1 in cancer patients. Increased FOXD2-AS1 was a risk factor of OS and DFS in cancer patients, suggesting FOXD2-AS1 may be a potential biomarker in human cancers
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
